Trials / Completed
CompletedNCT02744339
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Evaluation of the Pharmacodynamic Effects of Riociguat in Subjects With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction in a Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to • Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary hypertension and heart failure with preserved ejection fraction The secondary objectives of this study are to * Assess safety and tolerability of riociguat in this study population * Assess changes in dimensions of left and right ventricles and cardiac function parameters using cardiac magnetic resonance imaging
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riociguat | Adempas up-titrated to max. 1.5mg TID |
| DRUG | Placebo | Placebo sham-titrated TID |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2020-08-01
- Completion
- 2020-09-01
- First posted
- 2016-04-20
- Last updated
- 2020-11-04
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT02744339. Inclusion in this directory is not an endorsement.